On Friday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Capstone Turbine Corp. (NASDAQ:CPST), Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Capstone Turbine Corp. (NASDAQ:CPST), with shares declined -2.72%, closed at $0.66.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), with shares dropped -6.91%, settled at $6.06.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), with shares dipped -6.90%, and closed at $15.39.

Amicus Therapeutics, Inc. (NASDAQ:FOLD), plummeted -6.82%, and closed at $11.61.

Latest NEWS regarding these Stocks are depicted underneath:

Capstone Turbine Corp. (NASDAQ:CPST)

Formerly on March 4, Capstone Turbine Corp. (CPST), the world’s leading clean technology manufacturer of microturbine energy systems, declared that it received an order to upgrade the Irvine Ranch Water District’s Michelson Water Recycling Plant in Irvine, California with five C200 microturbines.

Regatta Solutions Inc., Capstone’s distributor in California, secured the order, which is predictable to be commissioned in early 2016. Once commissioned, the microturbines will cleanly and effectively operate on the biogas, or “green waste”, produced on-site from municipal solid waste.

Capstone microturbines will be installed in a grid connect configuration to provide electricity to the recycling plant in parallel with the local utility. The site will comprise a biogas conditioning skid to compress the plant’s biogas for use in the microturbine engines. The microturbines are deployed in a combined heat and power (CHP) configuration. The exhaust from the microturbines will be captured using heat exchangers to provide hot water for process heating the plant, thus reducing the need for natural gas and providing the highest system efficiency possible.

“Capstone microturbines offer redundancy and the ability to be sequenced to load follow automatically based on gas availability and the electrical loads at the site,” said Jim Crouse, Executive Vice President of Sales and Marketing at Capstone Turbine. “With Capstone microturbines, businesses are able to reduce operational expenditures while simultaneously assisting their local community,” added Crouse.

Capstone Turbine Corporation develops, manufactures, markets, and services microturbine technology solutions for use in stationary distributed power generation applications worldwide. The corporation offers microturbine units, subassemblies, components, and various accessories for applications, counting cogeneration comprising combined heat and power (CHP) and integrated CHP, in addition to combined cooling, heat, and power; and renewable energy, natural resources, and critical power supply.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

Formerly on March 16, Progenics Pharmaceuticals, Inc. (PGNX), declared its results of operations for the fourth quarter and year-end 2014.

“We have stated noteworthy progress in recent months, and start 2015 with a pivotal trial underway for Azedra, two Phase 3-ready prostate cancer programs, and a strong balance sheet to support our high-value pipeline,” stated Mark Baker, CEO of Progenics. “The data emerging from our PSMA ADC and 1404 programs are quite impressive, demonstrating the potential of these product candidates to change the way prostate cancer is diagnosed, monitored and treated. Following positive interactions with the FDA, we are working to finalize the Phase 3 protocol for 1404, our novel imaging agent. In addition, we have re-launched the pivotal Phase 2 trial for our ultra-orphan product candidate, Azedra, in metastatic pheochromocytoma and paraganglioma, and look forward to concluding enrollment in the trial by year-end. We remain focused on advancing these late-stage programs forward in an efficient manner while ongoing to build meaningful value for our shareholders.”

Fourth quarter proceed resulted in a loss of $0.6 million, primarily from RELISTOR royalty losses due to Salix’s plan to accelerate the reduction of wholesaler inventory levels and substantially cease all sales efforts to wholesalers in the fourth quarter of 2014. This compares to proceeds of $3.0 million due to RELISTOR royalty revenue in the fourth quarter of 2013.

Full year 2014 proceed was $44.4 million, up from $7.9 million in the preceding year, reflecting an raise in partnership proceed of $39.6 million, primarily resulting from the recognition of the $40.0 million milestone from Salix, partially offset by a $2.8 million decrease in RELISTOR royalty revenue to $3.1 million, contrast to $5.9 million in 2013.

Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The corporation’s primary clinical-stage product candidates comprise prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has accomplished Phase II testing in chemotherapy-practiced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has accomplished Phase II testing, in addition to acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)

Formerly on February 24, Infinity Pharmaceuticals, Inc. (INFI), declared its full-year 2014 financial results and ongoing progress with duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. Infinity anticipates that it will report topline data from DYNAMOTM, a Phase 2 study of duvelisib in patients with refractory indolent non-Hodgkin lymphoma (iNHL), in the second half of 2015 following the completion of patient enrollment in the first half of the year. Infinity also anticipates to complete enrollment of DUOTM, a Phase 3 study of duvelisib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), in the second half of 2015. Additionally, Infinity anticipates that three corporation-sponsored clinical studies of duvelisib will be initiated in 2015, counting the first clinical study of duvelisib in combination with venetoclax (ABT-199).

Key highlights comprise the following:

Initiated DYNAMO+R, a Phase 3 study in patients with formerly treated follicular lymphoma: In December 2014, Infinity declared the initiation of DYNAMO+R, a Phase 3, randomized, double-blind, placebo-controlled study comparing duvelisib plus Rituxan® (rituximab) to placebo plus Rituxan in about 400 patients with formerly treated follicular lymphoma. The primary endpoint of the study is progression-free survival.

Initiated two additional studies of duvelisib: As part of Infinity’s development strategy to demonstrate the therapeutic potential of duvelisib in multiple indications and lines of treatment, the corporation recently declared that it has initiated its Phase 1b/2 clinical study in patients with formerly untreated follicular lymphoma, which is designed to evaluate the safety and activity of duvelisib in combination with Gazyva® (obinutuzumab) or Rituxan. The corporation also declared recently that it has initiated the Phase 1b clinical study of duvelisib in combination with Gazyva in patients with CLL whose disease has progressed following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor.

Infinity Pharmaceuticals, Inc., a drug discovery and development corporation, focuses on discovering, developing, and delivering medicines to people with difficult-to-treat diseases. Its lead product candidate comprises IPI-145, an oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies and inflammatory diseases.

Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Amicus Therapeutics, Inc. (FOLD), declared that it has met very recently with regulatory authorities in Europe and the U.S. to talk about the approval pathways for the oral small molecule pharmacological chaperone migalastat HCl as a precision medicine monotherapy for Fabry patients who have amenable genetic mutations.

Meeting with European Rapporteurs:

The Corporation held a meeting with the assigned European Rapporteurs to talk about the forthcoming marketing authorization application (MAA) for migalastat monotherapy. Amicus Chief Medical Officer Dr. Jay Barth led the Amicus delegation at the meeting in Europe last week. It was the first face-to-face meeting with the assigned Rapporteurs on the projected dossier for migalastat monotherapy. The European Medicines Agency (EMA) assigns Rapporteurs to review the data in the MAA in detail and to provide guidance to sponsors during the regulatory approval process. The meeting was highly successful for Amicus. The key takeaways from the meeting comprise:

• Acknowledgment from the Rapporteurs of the continued noteworthyunmet need in Fabry disease, and the need for innovative treatment options such as migalastat monotherapy.
• The Rapporteurs commented favorably upon the quality and quantity of the migalastat data presented, which comprised of data from the two largest Phase 3 studies ever conducted in Fabry disease and over 400 patient years of data.
• The Rapporteurs also noted that the Amicus clinical development plan followed the preceding scientific guidance from EMA.
• The Rapporteurs agreed that Amicus may submit its MAA for migalastat monotherapy under the Full Approval pathway in the EU.
• The Rapporteurs indicated support for Amicus to request Accelerated Assessment in view of the migalastat data and the major public health interest that exists for Fabry patients.

Amicus Therapeutics, Inc., a biopharmaceutical corporation, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.